Navigation Links
MetaStat, Inc. Executes Two New Licenses
Date:4/27/2012

of anti-metastatic drugs. There are currently no FDA approved drugs to target and kill these metastatic cells.

"Isolation, Gene Expression, and Chemotherapeutic Resistance of Motile Cancer Cells" describes an "artificial blood vessel" that was developed to mimic the chemical attraction exerted on highly metastatic cells by the tumor vasculature. We believe this is the first method available to actually isolate, collect, genetically profile, and determine chemotherapeutic resistance of a pure population of metastatic cancer cells from a tumor. Previously, attempts to genetically profile these dangerous cells were difficult because tumor samples available for analysis contained large proportions of proliferative and structural cells and only a tiny proportion of metastatic cells.

"Human Invasion Signature for Prognosis of Metastatic Risk," another result of our proprietary ability to isolate metastatic cells, describes the actual causative gene signature of metastatic cells. This approach contrasts with currently available technology that purports to evaluate risk of cancer recurrence by relying upon correlative mathematical algorithms developed through the statistical analysis of whole tumor tissue samples.

About MetaStat, Inc.

MetaStat is a life science company focused on the development and commercialization of proprietary clinical diagnostic tests that predict the probability of systemic hematogenous (blood borne) metastasis of cancer, as well as companion therapeutics to prevent this deadly spread. We believe our initial product, the MetaSite Breast™ test, will predict the probability that cancer will be disseminated by this means to other organs in the body. MetaSite Breast is expected to be an important guide to treatment strategies for breast cancer patients and their doctors because metastasis is responsible for almost 90% of fatalities from breast cancer.  Further, the platform technology underlying thi
'/>"/>

SOURCE MetaStat, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. PhotoVoltaic Solar Cells, Inc. Completes Share Exchange with MetaStat, Inc.
2. MetaStat, Inc. Completes Share Exchange with PhotoVoltaic Solar Cells, Inc.
3. Ampio Pharmaceuticals Executes License and Development Agreement with Daewoong Co. Ltd. to Commercialize Zertane™ in South Korea
4. Adeona Executes Agreement to Initiate Phase IIb Clinical Trial of Proprietary Zinc-Based Therapy in Lou Gehrigs Disease (ALS)
5. Adeona Executes Manufacturing and Supply Agreement with TG United for reaZin™
6. Soligenix Executes Exclusive License with the University of Colorado for Vaccine Thermostabilization Technology
7. Alexza Executes $15 million Working Capital Loan with Hercules Technology Growth Capital, Inc.
8. Kun Run Biotechnology, Inc. Executes Purchase Agreements for Approximately $8 Million Private Placement
9. Obecure Executes Licensing and Clinical Supply Agreement With Farmaceutici-Formenti SPA for Extended Release Formulation of Betahistine
10. Transgenomic, Inc. Executes License Option agreement for Parkinsons Disease Diagnostic Markers with Gene Solutions, LLC
11. DOR BioPharma, Inc. Executes $400,000 Equity Investment Agreement With Numoda Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... 2014 The global high content screening market ... ,Threat of Obsolescence, wherein technologies as well as their ... biotechnology companies as well as academic and government institutes ... a powerful research tool in drug discovery. The high ... the high content screening market. In high content screening, ...
(Date:10/1/2014)... 2014  Abaxis, Inc. (NasdaqGS: ABAX ), ... for the medical, research, and veterinary markets worldwide and ... markets in the United States , ... agreement with Patterson Veterinary Supply. Patterson ... of Abaxis veterinary products throughout the United ...
(Date:10/1/2014)... BOSTON , Oct. 1, 2014   ... market-leading provider of Anesthesia Information Management Systems (AIMS), ... Systems, LLC , a wholly owned subsidiary of ... healthcare information systems and connectivity solutions.  ... http://photos.prnewswire.com/prnh/20140930/149407 This partnership ...
Breaking Medicine Technology:High Content Screening Market by Instruments (Cell Imaging and Analysis System), by Applications (Primary and Secondary Screening, Target Identification and Validation, Toxicity Studies, Compound Profiling), Software & Services - Global Forecasts to 2High Content Screening Market by Instruments (Cell Imaging and Analysis System), by Applications (Primary and Secondary Screening, Target Identification and Validation, Toxicity Studies, Compound Profiling), Software & Services - Global Forecasts to 3Abaxis Announces Distribution Agreement with Patterson Veterinary Supply 2Abaxis Announces Distribution Agreement with Patterson Veterinary Supply 3Abaxis Announces Distribution Agreement with Patterson Veterinary Supply 4Plexus IS' Anesthesia Documentation Solution Strengthens NextGen Healthcare Product Offering 2Plexus IS' Anesthesia Documentation Solution Strengthens NextGen Healthcare Product Offering 3
... , , , LIBERTYVILLE, Ill., ... today that the Office of Orphan Products Development of the Food ... for the treatment of Spinal Muscular Atrophy. , , ... for Spinal Muscular Atrophy has ever reached the important stage of ...
... , , , ... Forest Laboratories today announced that results of four phase III ... The Lancet showing that roflumilast, a phosphodiesterase 4 ... to severe COPD. , , COPD is ...
Cached Medicine Technology:Families of Spinal Muscular Atrophy Receives FDA Orphan Drug Designation For Quinazoline495 For The Treatment of Spinal Muscular Atrophy 2Families of Spinal Muscular Atrophy Receives FDA Orphan Drug Designation For Quinazoline495 For The Treatment of Spinal Muscular Atrophy 3Families of Spinal Muscular Atrophy Receives FDA Orphan Drug Designation For Quinazoline495 For The Treatment of Spinal Muscular Atrophy 4Four Studies Published in The Lancet Show roflumilast (Daxas(R)), a New Oral Approach to COPD, Improves Lung Function and Reduces Exacerbations 2Four Studies Published in The Lancet Show roflumilast (Daxas(R)), a New Oral Approach to COPD, Improves Lung Function and Reduces Exacerbations 3Four Studies Published in The Lancet Show roflumilast (Daxas(R)), a New Oral Approach to COPD, Improves Lung Function and Reduces Exacerbations 4Four Studies Published in The Lancet Show roflumilast (Daxas(R)), a New Oral Approach to COPD, Improves Lung Function and Reduces Exacerbations 5Four Studies Published in The Lancet Show roflumilast (Daxas(R)), a New Oral Approach to COPD, Improves Lung Function and Reduces Exacerbations 6Four Studies Published in The Lancet Show roflumilast (Daxas(R)), a New Oral Approach to COPD, Improves Lung Function and Reduces Exacerbations 7Four Studies Published in The Lancet Show roflumilast (Daxas(R)), a New Oral Approach to COPD, Improves Lung Function and Reduces Exacerbations 8Four Studies Published in The Lancet Show roflumilast (Daxas(R)), a New Oral Approach to COPD, Improves Lung Function and Reduces Exacerbations 9
(Date:10/2/2014)... HealthDay Reporter WEDNESDAY, ... out all the stops to rescue surgical patients in ... cost of such heroism is questionable, a new study ... better at saving elderly patients with life-threatening complications after ... intensity, said senior author Dr. Amir Ghaferi. He is ...
(Date:10/1/2014)... that more than 80 per cent of bowel cancers ... found that medicines called ,JAK inhibitors, halted tumour growth ... present in more than 80 per cent of bowel ... in clinical trials, for diseases including rheumatoid arthritis, psoriasis, ... the second-most common cancer in Australia with nearly 17,000 ...
(Date:10/1/2014)... Despite a policy focus on expanding access to ... population continues to have significant dental disease. In ... the American Dental Association , researchers from Tufts ... of Dental Medicine report on the first large-scale ... provided by caregivers to adults with developmental disabilities. ...
(Date:10/1/2014)... 01, 2014 Bedros Keuilian is not ... Camp fitness boot camps, he’s also considered the leading ... with sold out business summits, a line of high-demand ... to a recent Spike TV reality show to his ... is the time for personal trainers and fitness business ...
(Date:10/1/2014)... FARMINGTON, Conn. (PRWEB) October 01, 2014 ... its company, including a redefined mission and visual ... the power of partnering with them to create ... more agile brand that focuses on empowering customers ... benefits communications. , The crown jewel of the ...
Breaking Medicine News(10 mins):Health News:'High-Intensity' Hospitals Save More Elderly After Surgery: Study 2Health News:'High-Intensity' Hospitals Save More Elderly After Surgery: Study 3Health News:Eighty percent of bowel cancers halted with existing medicines 2Health News:To improve oral health of adults with developmental disabilities, support caregivers 2Health News:To improve oral health of adults with developmental disabilities, support caregivers 3Health News:Bedros Keuilian Shares Tips on Selling Personal Training for the Holidays 2Health News:Bedros Keuilian Shares Tips on Selling Personal Training for the Holidays 3Health News:Farmington Company Launches Rebrand and New Positioning 2
... internet about human incidence of bird flu in Quebec is ... ,Dr Patrick Dolce, the man at the helm ... "Everything is false; there is no patient, no nothing." ... devoted to avian flu which had enabled a report of ...
... C last week. Public health department in Toronto has alerted ... contagious and the man who died happened to have frequented ... ,Although only a single case has been notified, owing to ... public to be cautious.,Meningitis C is a contagious disease caused ...
... about memory could offer an early warning system for ... at Rush University Medical Center. The researchers have found// ... changes in the brain related to Alzheimer's disease. Their ... Neurology. ,The researchers looked at the association ...
... for termination of early pregnancies, might be helpful to ... from the University of California, whose work has been ... licensed drug that blocks the hormone progesterone. In pregnancy, ... If it is depleted the developing fetus can get ...
... and colleagues at four other medical centers have launched ... may contribute to early atherosclerosis. ,“If we can ... who have a genetic predisposition to develop atherosclerosis, we ... stroke sooner and more aggressively,” said David Herrington, M.D., ...
... an imbalance in the overall treatment has lead to the ... of effective dietary care are met with. ,According ... not yet analyzed the nutritional value of the diets the ... any miscalculation in their prescription of menus can lead to ...
Cached Medicine News:Health News:Memory Complaints Are Associated With Alzheimer's Disease 2Health News:Memory Complaints Are Associated With Alzheimer's Disease 3Health News:Breast Cancer Prevention Using Abortion Drug Considered 2Health News:Study Underway to Identify Genes Contributing to Heart Attack Risk 2Health News:Hospital Food Needs Improvement to Meet the Nutritional Needs of the Patient 2
2 mm wide curved tip. Round handle....
3 mm disposable Lance blade. Can fit in to the N0521 Storz handle....
Consist of 6 disposable bevel blades (N0522) and chuck handle (0521). Malleable shafts. Designated most popular model or size....
1.5 mm x 12 mm tip. Angled 15 degrees. Teflon coated with diathermy attachment....
Medicine Products: